Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | — | 2 | — | — | — | 2 |
Hepatitis | D006505 | — | K75.9 | — | 2 | — | — | — | 2 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | 2 | — | — | — | 2 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
Drug common name | BIMIRALISIB |
INN | bimiralisib |
Description | Bimiralisib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform. |
Classification | Small molecule |
Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1 |
PDB | — |
CAS-ID | 1225037-39-7 |
RxCUI | — |
ChEMBL ID | CHEMBL4084907 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 6Z3QHB00LB (ChemIDplus, GSRS) |